Search results
Results from the WOW.Com Content Network
The next day, Boston Scientific increased their bid to $25 billion, followed the next day by Johnson & Johnson increasing their bid to $24.2 billion. It was not until January 17 that Boston Scientific produced a new offer of $27.2 billion ($80 per share), with the help of Abbott Laboratories. Abbott agreed to purchase $1.4 billion of Boston ...
Shares of the medical device maker rose 1.5% in afternoon trading. The approval makes the device, branded Agent, the first drug-coated balloon catheter in the U.S. to treat coronary in-stent ...
"AICD" was trademarked by the Boston Scientific corporation, so the more generic "ICD" is preferred terminology. A single chamber ICD with its right ventricular lead connected into the header; note, starting from the end of the lead, the tip and adjacent first ring, used to sense the cardiac electrical activity and stimulate the right ventricle ...
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, [2] is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular ...
Boston Scientific's Flextome is the most widely used cutting balloon. Cutting balloons have also been used in the treatment of refractory or recurrent laryngotracheal stenosis , particularly in cases where a dense ring of circumferential fibrosis has formed in the trachea or either bronchus '.
A coronary stent is a tube-shaped device placed in the coronary arteries that supply blood to the heart, to keep the arteries open in patients suffering from coronary heart disease. The vast majority of stents used in modern interventional cardiology are drug-eluting stents (DES).
Medtronic's main competitors in the cardiac rhythm field include Boston Scientific and St. Jude Medical. In 1997, Medtronic opened a production site for implantable pacemakers and brain pacemakers in Tolochenaz, Switzerland. One in five pacemakers implanted globally today is made here. The site is also used as a European training centre for ...
Boston Scientific's Lotus Valve system was awarded CE approval in October 2013. It allows the final position to be assessed and evaluated before release and has been designed to minimise regurgitation. [12] Boston Scientific has since retired the device as of January 11, 2021. [13]